pcDNA-HA-ER D538G Citations (3)

Originally described in: ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S Nat Genet. 2013 Dec;45(12):1439-45. doi: 10.1038/ng.2822. Epub 2013 Nov 3. PubMed Journal

---

Articles Citing pcDNA-HA-ER D538G

Articles
XBP1 increases transactivation of somatic mutants of ESR1 and loss of XBP1 reverses endocrine resistance conferred by gain-of-function Y537S ESR1 mutation. Barua D, Abbasi B, Gupta A, Gupta S. Heliyon. 2020 Oct 10;6(10):e05217. doi: 10.1016/j.heliyon.2020.e05217. eCollection 2020 Oct. PubMed
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Li Z, McGinn O, Wu Y, Bahreini A, Priedigkeit NM, Ding K, Onkar S, Lampenfeld C, Sartorius CA, Miller L, Rosenzweig M, Cohen O, Wagle N, Richer JK, Muller WJ, Buluwela L, Ali S, Bruno TC, Vignali DAA, Fang Y, Zhu L, Tseng GC, Gertz J, Atkinson JM, Lee AV, Oesterreich S. Nat Commun. 2022 Apr 19;13(1):2011. doi: 10.1038/s41467-022-29498-9. PubMed
YAP inhibits ERalpha and ER(+) breast cancer growth by disrupting a TEAD-ERalpha signaling axis. Li X, Zhuo S, Zhuang T, Cho YS, Wu G, Liu Y, Mu K, Zhang K, Su P, Yang Y, Zhang CC, Zhu J, Jiang J. Nat Commun. 2022 Jun 2;13(1):3075. doi: 10.1038/s41467-022-30831-5. PubMed

If you have published an article using this material, please email us at to have your article added to this page.